Ferrer M, et al. - Researchers determined the potential predictors of the speed of symptom return after omalizumab treatment cessation, by pooling phase III randomized controlled trial (RCT) data from ASTERIA I (n=319; 6x4-weekly injections of omalizumab 75, 150, 300 mg or placebo) and ASTERIA II (n=323; 3x4-weekly injections of omalizumab 75, 150, 300 mg or placebo). For the selection of predictive variables, the least absolute shrinkage and selection operator (LASSO) regularization regression model was used. Of 746 variables assessed, baseline UAS7 (urticaria activity score over 7 days) and early treatment response showed utility in the estimation of the probability of rapid symptom return in chronic spontaneous urticaria patients who discontinued treatment with omalizumab.